Wise R A, Carlezon W A
Department of Psychology, Concordia University, Montreal, Canada.
Synapse. 1994 Jul;17(3):155-9. doi: 10.1002/syn.890170303.
Injections of the selective D2 dopamine agonist bromocriptine (5.0 mg/kg, IP) produced progressively stronger locomotion over 10 days of repeated testing. Concurrent treatment with either the D1 antagonist SCH 23390 (0.01 or 0.1 mg/kg, IP) or the D2 antagonist raclopride (0.1 or 1.0 mg/kg, IP) suppressed bromocriptine-induced locomotion on treatment days and attenuated or blocked the progressive increases in locomotion that accompanied repeated injections of bromocriptine alone. The fact that D1 and D2 antagonists each block the acute actions of bromocriptine and attenuate the development of bromocriptine sensitization is suggested to imply a striatal rather than a ventral tegmental mechanism for the sensitization produced by repeated treatments with direct dopamine agonists.
注射选择性D2多巴胺激动剂溴隐亭（5.0毫克/千克，腹腔注射），在连续10天的重复测试中产生了逐渐增强的运动能力。同时给予D1拮抗剂SCH 23390（0.01或0.1毫克/千克，腹腔注射）或D2拮抗剂雷氯必利（0.1或1.0毫克/千克，腹腔注射）进行治疗，在给药当天抑制了溴隐亭诱导的运动，并减弱或阻断了单独重复注射溴隐亭时运动能力的逐渐增加。D1和D2拮抗剂均能阻断溴隐亭的急性作用并减弱溴隐亭敏感性的发展，这一事实表明，直接多巴胺激动剂重复治疗产生的敏感性机制是纹状体而非腹侧被盖区机制。
